G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Estrogen Signaling and Cardiovascular Research

Executive Summary: G-1 (CAS 881639-98-1) is a potent, selective GPR30 agonist with high affinity (Ki ~11 nM) for the G protein-coupled estrogen receptor, enabling rapid, non-genomic estrogen signaling studies (Wang et al., 2021). It shows minimal binding to classical nuclear estrogen receptors ERα and ERβ even at micromolar concentrations. In breast cancer cell lines SKBr3 and MCF7, G-1 inhibits cell migration at sub-nanomolar IC50 values. Chronic G-1 administration in rat heart failure models reduces cardiac fibrosis and normalizes adrenergic receptor expression. APExBIO offers G-1 (SKU B5455) as a crystalline solid for reproducible, high-sensitivity research applications (product page).

Biological Rationale

Estrogen signaling is mediated via classical nuclear receptors ERα and ERβ, as well as the membrane-associated G protein-coupled estrogen receptor GPR30 (GPER1) (Wang et al., 2021). GPR30 is primarily localized to the endoplasmic reticulum and mediates rapid, non-genomic responses to estrogens. G-1 is a synthetic, high-affinity agonist specific for GPR30, showing minimal cross-reactivity with ERα and ERβ. This specificity enables researchers to dissect GPR30-dependent pathways in physiological and pathological contexts, including cardiovascular, cancer, and immune system models. Rapid estrogen signaling via GPR30 regulates intracellular calcium mobilization, PI3K/PIP3 signaling, and modulates immune cell function (review). This article extends the mechanistic detail presented in 'G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid ...' by providing new quantitative benchmarks and workflow guidance.

Mechanism of Action of G-1 (CAS 881639-98-1), a Selective GPR30 Agonist

G-1 binds GPR30 with nanomolar affinity (Ki ≈ 11 nM) under standard assay conditions (pH 7.4, 25°C) (APExBIO). Upon G-1 binding, GPR30 activates G protein-dependent signaling cascades, including:

• Elevation of intracellular calcium (EC50 = 2 nM; measured in SKBr3 breast cancer cells, 37°C, physiological buffer).
• PI3K-mediated nuclear accumulation of PIP3, observed within 5–15 min of G-1 exposure (10 nM–1 µM) in cell culture.
• Transcriptional modulation of target genes, including normalization of β1-adrenergic receptor and upregulation of β2-adrenergic receptor in heart tissue (Wang et al., 2021).

G-1 does not significantly bind or activate ERα or ERβ at concentrations up to 10 µM, ensuring pathway specificity (APExBIO).

Evidence & Benchmarks

• G-1 inhibits migration of SKBr3 breast cancer cells (IC50 = 0.7 nM) and MCF7 cells (IC50 = 1.6 nM) in transwell assays (serum-free, 37°C, 24 h) (APExBIO).
• Activation of GPR30 by G-1 increases intracellular calcium in SKBr3 cells with EC50 = 2 nM (fluorescence-based calcium assay, 37°C) (Wang et al., 2021).
• In vivo, chronic G-1 administration (10 µg/kg, i.p., daily for 4 weeks) in ovariectomized, heart-failure model Sprague-Dawley rats reduces brain natriuretic peptide (BNP), inhibits cardiac fibrosis, and improves contractility (Wang et al., 2021).
• G-1’s effects in immune modulation, such as normalization of splenic CD4+ T lymphocyte proliferation after hemorrhagic shock, are abrogated by GPR30 antagonist G15 but not by ERβ agonists (Wang et al., 2021, Fig. 1).
• G-1 stock solutions are stable at >10 mM in DMSO, soluble at ≥41.2 mg/mL in DMSO; insoluble in water and ethanol (20–25°C) (APExBIO).

For more protocol optimization, see 'Optimizing Cell Assays with G-1 (CAS 881639-98-1), a Sele...', which focuses on cell viability and cytotoxicity workflows. This article updates with new in vivo immunological findings.

Applications, Limits & Misconceptions

Applications

• Dissection of GPR30-mediated calcium and PI3K signaling in cell lines and primary cell cultures.
• Modeling non-genomic estrogen actions in cardiovascular pathology, including cardiac fibrosis and heart failure (Wang et al., 2021).
• Inhibition of breast cancer cell migration in vitro, providing a tool for oncology research.
• Immune function studies, especially normalization of CD4+ T lymphocyte proliferation after trauma or inflammatory insult.
• Benchmark tool for distinguishing GPR30 versus ERα/ERβ mediated pathways in pharmacologic research.

Common Pitfalls or Misconceptions

• Not suitable for nuclear ERα/ERβ pathway activation: G-1 shows negligible activity at ERα/ERβ even at high concentrations (APExBIO).
• Insoluble in water and ethanol: G-1 must be dissolved in DMSO; aqueous or ethanolic buffers result in precipitation.
• Not recommended for long-term solution storage: Stock solutions should be kept at -20°C and used within a short period to avoid degradation.
• Effectiveness depends on GPR30 expression: Cells or tissues lacking GPR30 will not respond to G-1.
• Off-target effects at extreme concentrations: Above 10 µM, non-specific effects may occur; titrate carefully (review).

For additional boundaries in immune modeling, 'G-1 (CAS 881639-98-1): Unlocking GPR30's Role in Immune M...' provides advanced mechanistic analysis; this article clarifies application limits for oncology and cardiovascular endpoints.

Workflow Integration & Parameters

• Preparation: Dissolve G-1 in DMSO at ≥10 mM. Warming (37°C) and ultrasonic bath can enhance solubility. Filter sterilize if needed.
• Storage: Store solid at -20°C. Stock DMSO solutions stable at -20°C for short-term (≤1 week); avoid repeated freeze-thaw cycles.
• Working concentrations: For in vitro, use 0.1–100 nM for GPR30 activation; confirm GPR30 expression by RT-qPCR or Western blot.
• Controls: Include vehicle (DMSO), ERα/ERβ agonists/antagonists, and GPR30 antagonist (e.g., G15) for pathway specificity.
• Documentation: Report cell line, passage, buffer composition, and temperature for reproducibility.

See G-1 (CAS 881639-98-1), a selective GPR30 agonist (APExBIO, SKU B5455) for product specifications and ordering.

Conclusion & Outlook

G-1 (CAS 881639-98-1) is a gold-standard selective GPR30 agonist for dissecting rapid estrogen signaling. Its atomic, reproducible effects in cardiovascular and oncology research are well-established. By leveraging G-1’s high selectivity and potency, researchers can clarify the distinct roles of GPR30 in health and disease. APExBIO’s B5455 G-1 is an indispensable reagent for high-precision endocrine, cancer, and immunology research workflows. Ongoing studies will further define GPR30’s therapeutic potential and expand applications into translational models.